Antonia Serrano

List of Publications by Year
in descending order

116 papers	4,424 citations	117625 34 h-index	128289 60 g-index
117 all docs	117 docs citations	117 times ranked	5079 citing authors

#	Article	IF	Citations
1	Acute stress and alcohol exposure during adolescence result in an anxious phenotype in adulthood: Role of altered glutamate/endocannabinoid transmission mechanisms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110460.	4.8	13
2	Repeated Restraint Stress and Binge Alcohol during Adolescence Induce Long-Term Effects on Anxiety-like Behavior and the Expression of the Endocannabinoid System in Male Rats. Biomedicines, 2022, 10, 593.	3.2	2
3	Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder. Biomedicines, 2022, 10, 947.	3.2	5
4	Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders. Brain Sciences, 2022, 12, 588.	2.3	4
5	Attenuation of oleoylethanolamide-induced reduction of alcohol consumption in adult rats exposed intermittently to alcohol during adolescence. Neuroscience Letters, 2022, 781, 136670.	2.1	2
6	Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex. Biomedicines, 2022, 10, 1137.	3.2	0
7	Sexâ€specific behavioral and neurogenic responses to cocaine in mice lacking and blocking dopamine <scp>D1</scp> or dopamine <scp>D2</scp> receptors. Journal of Comparative Neurology, 2021, 529, 1724-1742.	1.6	1
8	Abrupt cessation of reboxetine along alcohol deprivation results in alcohol intake escalation after reinstatement of drinking. Addiction Biology, 2021, 26, e12957.	2.6	3
9	Selective inhibition of monoacylglycerol lipase is associated with passive coping behavior and attenuation of stress-induced dopamine release in the medial prefrontal cortex. Neurobiology of Stress, 2021, 14, 100293.	4.0	5
10	Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. Scientific Reports, 2021, 11, 13629.	3.3	5
11	Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain. Brain Structure and Function, 2021, 226, 2243-2264.	2.3	2
12	Evaluation of neurotrophic factors and education level as predictors of cognitive decline in alcohol use disorder. Scientific Reports, 2021, 11, 15583.	3.3	11
13	Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease. Biomedicines, 2021, 9, 1207.	3.2	6
14	Influence of gender and education on cocaine users in an outpatient cohort in Spain. Scientific Reports, 2021, 11, 20928.	3.3	7
15	Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1Î². Neuropharmacology, 2020, 162, 107840.	4.1	16
16	D-Pinitol from Ceratonia siliqua Is an Orally Active Natural Inositol That Reduces Pancreas Insulin Secretion and Increases Circulating Ghrelin Levels in Wistar Rats. Nutrients, 2020, 12, 2030.	4.1	22
17	Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients. Scientific Reports, 2020, 10, 17163.	3.3	8
18	COXâ€2 Inhibition Antagonizes Intraâ€Accumbens 2â€Arachidonoylglycerolâ€“Mediated Reduction in Ethanol Selfâ€Administration in Rats. Alcoholism: Clinical and Experimental Research, 2020, 44, 2158-2165.	2.4	2

#	Article	IF	Citations
19	Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2020, 11, 730.	3.5	78
20	Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases. Journal of Psychopharmacology, 2020, 34, 1250-1260.	4.0	8
21	Differential hepatoprotective role of the cannabinoid CB₁ and CB₂ receptors in paracetamolâ€induced liver injury. British Journal of Pharmacology, 2020, 177, 3309-3326.	5.4	13
22	Variation in chemokines plasma concentrations in primary care depressed patients associated with Internet-based cognitive-behavioral therapy. Scientific Reports, 2020, 10, 1078.	3.3	11
23	Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109958.	4.8	14
24	Bupropion, a possible antidepressant without negative effects on alcohol relapse. European Neuropsychopharmacology, 2019, 29, 756-765.	0.7	2
25	Oleoylethanolamide Modulates BDNF-ERK Signaling and Neurogenesis in the Hippocampi of Rats Exposed to Î”9-THC and Ethanol Binge Drinking During Adolescence. Frontiers in Molecular Neuroscience, 2019, 12, 96.	2.9	23
26	Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. PLoS ONE, 2019, 14, e0213791.	2.5	18
27	Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants. Neuropharmacology, 2019, 149, 212-220.	4.1	30
28	Serotonin is the main tryptophan metabolite associated with psychiatric comorbidity in abstinent cocaine-addicted patients. Scientific Reports, 2019, 9, 16842.	3.3	15
29	Alcoholâ€induced cognitive deficits are associated with decreased circulating levels of the neurotrophin BDNF in humans and rats. Addiction Biology, 2019, 24, 1019-1033.	2.6	45
30	Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum. Neuropharmacology, 2019, 146, 184-197.	4.1	12
31	Ethanolâ€induced alterations in endocannabinoids and relevant neurotransmitters in the nucleus accumbens of fatty acid amide hydrolase knockout mice. Addiction Biology, 2019, 24, 1204-1215.	2.6	13
32	Neuroplastic and cognitive impairment in substance use disorders: a therapeutic potential of cognitive stimulation. Neuroscience and Biobehavioral Reviews, 2019, 106, 23-48.	6.1	44
33	Central administration of galanin Nâ€terminal fragment 1â€“15 decreases the voluntary alcohol intake in rats. Addiction Biology, 2019, 24, 76-87.	2.6	10
34	Lysophosphatidic acidâ€induced increase in adult hippocampal neurogenesis facilitates the forgetting of cocaineâ€contextual memory. Addiction Biology, 2019, 24, 458-470.	2.6	35
35	Systemic blockade of LPA1/3 lysophosphatidic acid receptors by ki16425 modulates the effects of ethanol on the brain and behavior. Neuropharmacology, 2018, 133, 189-201.	4.1	15
36	Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women. Addiction Biology, 2018, 23, 1242-1250.	2.6	20

#	Article	IF	Citations
37	Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotineâ€induced dopamine release in the mouse nucleus accumbens. Addiction Biology, 2018, 23, 723-734.	2.6	16
38	Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study. Addiction Biology, 2018, 23, 1251-1261.	2.6	4
39	PPARÎ±/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochemical Pharmacology, 2018, 157, 235-243.	4.4	9
40	Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake. Neuropsychopharmacology, 2018, 43, 1840-1850.	5.4	58
41	The adiponectin promoter activator NP-1 induces high levels of circulating TNFÎ± and weight loss in obese (fa/fa) Zucker rats. Scientific Reports, 2018, 8, 9858.	3.3	7
42	Higher Impulsivity As a Distinctive Trait of Severe Cocaine Addiction among Individuals Treated for Cocaine or Alcohol Use Disorders. Frontiers in Psychiatry, 2018, 9, 26.	2.6	22
43	Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure. Biochemical Pharmacology, 2018, 157, 244-257.	4.4	35
44	Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse. Frontiers in Molecular Neuroscience, 2018, 11, 490.	2.9	69
45	Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect of length of abstinence. Addiction Biology, 2017, 22, 1366-1377.	2.6	20
46	Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NFâ€kB danger signaling in rat frontal cortex and depressiveâ€like behavior induced by ethanol binge administration. Addiction Biology, 2017, 22, 724-741.	2.6	88
47	Long-lasting memory deficits in mice withdrawn from cocaine are concomitant to neuroadaptations in hippocampal basal activity, GABAergic interneurons and adult neurogenesis. DMM Disease Models and Mechanisms, 2017, 10, 323-336.	2.4	33
48	The impact of cocaine on adult hippocampal neurogenesis: Potential neurobiological mechanisms and contributions to maladaptive cognition in cocaine addiction disorder. Biochemical Pharmacology, 2017, 141, 100-117.	4.4	37
49	Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. Frontiers in Pharmacology, 2017, 8, 705.	3.5	18
50	Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity. Frontiers in Psychiatry, 2017, 7, 214.	2.6	25
51	Effects of Intermittent Alcohol Exposure on Emotion and Cognition: A Potential Role for the Endogenous Cannabinoid System and Neuroinflammation. Frontiers in Behavioral Neuroscience, 2017, 11, 15.	2.0	43
52	Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders. PLoS ONE, 2017, 12, e0187634.	2.5	32
53	Differences in the Rates of Drug Polyconsumption and Psychiatric Comorbidity among Patients with Cocaine Use Disorders According to the Mental Health Service. Journal of Psychoactive Drugs, 2017, 49, 306-315.	1.7	11
54	Comorbilidad psiquiÃ¡trica y valores plasmÃ¡ticos de 2-acilgliceroles en consumidores de alcohol en tratamiento ambulatorio. AnÃ¡lisis de las diferencias de gÃ©nero. Revista De Psicologia De La Salud, 2017, 29, 83.	0.5	15

#	Article	IF	Citations
55	Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFÎ±) as a potential biomarker of consumption and dual diagnosis. PeerJ, 2017, 5, e3926.	2.0	23
56	Environmental Enrichment, Age, and PPARÎ± Interact to Regulate Proliferation in Neurogenic Niches. Frontiers in Neuroscience, 2016, 10, 89.	2.8	19
57	Effects of Adolescent Intermittent Alcohol Exposure on the Expression of Endocannabinoid Signaling-Related Proteins in the Spleen of Young Adult Rats. PLoS ONE, 2016, 11, e0163752.	2.5	8
58	Role of the satiety factor oleoylethanolamide in alcoholism. Addiction Biology, 2016, 21, 859-872.	2.6	58
59	A place for the hippocampus in the cocaine addiction circuit: Potential roles for adult hippocampal neurogenesis. Neuroscience and Biobehavioral Reviews, 2016, 66, 15-32.	6.1	80
60	Antiobesity efficacy of GLPâ€1 receptor agonist liraglutide is associated with peripheral tissueâ€specific modulation of lipid metabolic regulators. BioFactors, 2016, 42, 600-611.	5.4	33
61	Single administration of recombinant ILâ€6 restores the gene expression of lipogenic enzymes in liver of fasting ILâ€6â€deficient mice. British Journal of Pharmacology, 2016, 173, 1070-1084.	5.4	10
62	Cocaine-induced behavioral sensitization decreases the expression of endocannabinoid signaling-related proteins in the mouse hippocampus. European Neuropsychopharmacology, 2016, 26, 477-492.	0.7	22
63	Both genetic deletion and pharmacological blockade of lysophosphatidic acid LPA1 receptor results in increased alcohol consumption. Neuropharmacology, 2016, 103, 92-103.	4.1	18
64	Cocaine-conditioned place preference is predicted by previous anxiety-like behavior and is related to an increased number of neurons in the basolateral amygdala. Behavioural Brain Research, 2016, 298, 35-43.	2.2	16
65	Pharmacological reduction of adult hippocampal neurogenesis modifies functional brain circuits in mice exposed to a cocaine conditioned place preference paradigm. Addiction Biology, 2016, 21, 575-588.	2.6	36
66	Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice. PLoS ONE, 2016, 11, e0157956.	2.5	21
67	Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context. Frontiers in Cellular Neuroscience, 2015, 9, 98.	3.7	43
68	Pharmacological activation of CB2 receptors counteracts the deleterious effect of ethanol on cell proliferation in the main neurogenic zones of the adult rat brain. Frontiers in Cellular Neuroscience, 2015, 9, 379.	3.7	21
69	Plasma Concentrations of BDNF and IGF-1 in Abstinent Cocaine Users with High Prevalence of Substance Use Disorders: Relationship to Psychiatric Comorbidity. PLoS ONE, 2015, 10, e0118610.	2.5	25
70	Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle. PLoS ONE, 2015, 10, e0145244.	2.5	31
71	Sex Differences in Psychiatric Comorbidity and Plasma Biomarkers for Cocaine Addiction in Abstinent Cocaine-Addicted Subjects in Outpatient Settings. Frontiers in Psychiatry, 2015, 6, 17.	2.6	31
72	Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high fat diet-induced steatosis in IL-6 deficient mice. DMM Disease Models and Mechanisms, 2015, 8, 721-31.	2.4	34

#	Article	IF	Citations
73	Plasma profile of proâ€inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric coâ€morbidity. Addiction Biology, 2015, 20, 756-772.	2.6	85
74	Cocaine-Induced Behavioral Sensitization Is Associated With Changes in the Expression of Endocannabinoid and Glutamatergic Signaling Systems in the Mouse Prefrontal Cortex. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	27
75	Treatment with a novel oleic-acidâ€“dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. DMM Disease Models and Mechanisms, 2015, 8, 1213-1225.	2.4	16
76	Oleoylethanolamide enhances Î²-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. DMM Disease Models and Mechanisms, 2014, 7, 129-41.	2.4	51
77	Localization of peroxisome proliferator-activated receptor alpha (PPARÃŽÂ±) and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) in cells expressing the Ca2+-binding proteins calbindin, calretinin, and parvalbumin in the adult rat hippocampus. Frontiers in Neuroanatomy, 2014, 8, 12.	1.7	16
78	Localization of the cannabinoid CB1 receptor and the 2-AG synthesizing (DAGLÃŽÂ±) and degrading (MAGL,) Tj ETQq0 0 0 rgBT /Overlo the adult rat hippocampus. Frontiers in Neuroanatomy, 2014, 8, 56.	1.7	27
79	Pharmacological blockade of either cannabinoid CB1 or CB2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rat. Frontiers in Integrative Neuroscience, 2014, 7, 106.	2.1	45
80	Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum. Frontiers in Integrative Neuroscience, 2014, 8, 22.	2.1	19
81	Preparation, characterization and in vivo evaluation of nanoemulsions for the controlled delivery of the antiobesity agent N-oleoylethanolamine. Nanomedicine, 2014, 9, 2761-2772.	3.3	10
82	The administration of atomoxetine during alcohol deprivation induces a time-limited increase in alcohol consumption after relapse. International Journal of Neuropsychopharmacology, 2014, 17, 1905-1910.	2.1	8
83	The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. International Journal of Neuropsychopharmacology, 2014, 17, 455-468.	2.1	37
84	Hyperplastic Obesity and Liver Steatosis as Long-Term Consequences of Suboptimal In Vitro Culture of Mouse Embryos1. Biology of Reproduction, 2014, 91, 30.	2.7	11
85	CB1 Blockade Potentiates Down-Regulation of Lipogenic Gene Expression in Perirenal Adipose Tissue in High Carbohydrate Diet-Induced Obesity. PLoS ONE, 2014, 9, e90016.	2.5	15
86	Computational and Biological Evaluation of N-octadecyl-Nâ€²-propylsulfamide, a Selective PPARÎ± Agonist Structurally Related to N-acylethanolamines. PLoS ONE, 2014, 9, e92195.	2.5	7
87	Dietâ€dependent modulation of hippocampal expression of endocannabinoid signalingâ€related proteins in cannabinoid antagonistâ€treated obese rats. European Journal of Neuroscience, 2013, 37, 105-117.	2.6	18
88	<scp>IL</scp>â€6 cooperates with peroxisome proliferatorâ€activated receptorâ€Î±â€ligands to induce liver fatty acid binding protein (<scp>LFABP</scp>) upâ€regulation. Liver International, 2013, 33, 1019-1028.	3.9	23
89	Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21. Bioorganic and Medicinal Chemistry, 2013, 21, 1708-1716.	3.0	19
90	Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addiction Biology, 2013, 18, 955-969.	2.6	40

#	Article	IF	Citations
91	Pharmacological Administration of the Isoflavone Daidzein Enhances Cell Proliferation and Reduces High Fat Diet-Induced Apoptosis and Gliosis in the Rat Hippocampus. PLoS ONE, 2013, 8, e64750.	2.5	58
92	Lipid Transmitter Signaling as a New Target for Treatment of Cocaine Addiction: New Roles for Acylethanolamides and Lysophosphatidic Acid. Current Pharmaceutical Design, 2013, 19, 7036-7049.	1.9	25
93	Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E817-E830.	3.5	10
94	Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARÎ± agonist, reduces body weight gain and plasma cholesterol in rats. DMM Disease Models and Mechanisms, 2012, 5, 660-70.	2.4	19
95	Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?. Current Obesity Reports, 2012, 1, 216-228.	8.4	11
96	Antiâ€obesity efficacy of LHâ€21, a cannabinoid CB₁ receptor antagonist with poor brain penetration, in dietâ€induced obese rats. British Journal of Pharmacology, 2012, 165, 2274-2291.	5.4	51
97	Differential Effects of Single Versus Repeated Alcohol Withdrawal on the Expression of Endocannabinoid Systemâ€Related Genes in the Rat Amygdala. Alcoholism: Clinical and Experimental Research, 2012, 36, 984-994.	2.4	65
98	Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration. Pharmacology Biochemistry and Behavior, 2012, 101, 1-7.	2.9	17
99	Oleoylethanolamide: Effects on hypothalamic transmitters and gut peptides regulating food intake. Neuropharmacology, 2011, 60, 593-601.	4.1	34
100	Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochemical Journal, 2011, 433, 175-185.	3.7	62
101	Obesity-dependent cannabinoid modulation of proliferation in adult neurogenic regions. European Journal of Neuroscience, 2011, 33, 1577-1586.	2.6	39
102	Reduction of body weight, liver steatosis and expression of stearoylâ€CoA desaturase 1 by the isoflavone daidzein in dietâ€induced obesity. British Journal of Pharmacology, 2011, 164, 1899-1915.	5.4	84
103	Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. , 2011, 132, 215-241.		153
104	Effects of the endogenous PPARâ€Î± agonist, oleoylethanolamide on MDMAâ€induced cognitive deficits in mice. Synapse, 2010, 64, 379-389.	1.2	42
105	Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discovery Today Disease Mechanisms, 2010, 7, e175-e183.	0.8	20
106	Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. European Journal of Medicinal Chemistry, 2009, 44, 4889-4895.	5.5	7
107	Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorganic and Medicinal Chemistry, 2008, 16, 10098-10105.	3.0	33
108	The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology, 2008, 54, 226-234.	4.1	75

#	Article	IF	Citations
109	Regulation of brain anandamide by acute administration of ethanol. Biochemical Journal, 2007, 404, 97-104.	3.7	101
110	Novel Sulfamide Analogs of Oleoylethanolamide Showing In Vivo Satiety Inducing Actions and PPARÎ± Activation. Journal of Medicinal Chemistry, 2007, 50, 389-393.	6.4	29
111	Role of cannabinoid CB2 receptors in glucose homeostasis in rats. European Journal of Pharmacology, 2007, 565, 207-211.	3.5	104
112	Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole â€“ LH 21. Neuropharmacology, 2006, 51, 358-366.	4.1	116
113	Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. European Journal of Pharmacology, 2006, 531, 282-284.	3.5	95
114	Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E923-E929.	3.5	53
115	Discovery of 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a Novel in Vivo Cannabinoid Antagonist Containing a 1,2,4-Triazole Motif. Journal of Medicinal Chemistry, 2004, 47, 2939-2942.	6.4	71
116	Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-Î±. Nature, 2003, 425, 90-93.	27.8	985